Kết quả hóa trị Paclitaxel trong ung thư vú tái phát di căn tại Bệnh viện Ung Bướu Hà Nội

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Vinh Quang Bùi, Văn Thịnh Thân

Ngôn ngữ: Vie

Ký hiệu phân loại: 616.994 +Cancers

Thông tin xuất bản: Tạp chí Y học Việt Nam 2023

Mô tả vật lý: 19-23

Bộ sưu tập: Metadata

ID: 408465

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Mô tả một số đặc điểm lâm sàng, cận lâm sàng và đánh giá kết quả hóa trị Paclitaxel trong ung thư vú tái phát di căn tại bệnh viện Ung bướu Hà Nội. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu trên 120 bệnh nhân ung thư vú tái phát di căn điều trị bằng phác đồ Paclitaxel tại bệnh viện Ung bướu Hà Nội từ tháng 01/2018 đến tháng 01/2022. Kết quả: 120 bệnh nhân tham gia vào nghiên cứu, tuổi trung bình là 59,6 ± 8,8 tuổi. Tỷ lệ đáp ứng chung của phác đồ là 37,5%, trung bình thời gian sống thêm không bệnh tiến triển (PFS) là 8,6±2,34 tháng. Tỷ lệ sống thêm toàn bộ 3 năm là 35,5%. Tỷ lệ sống thêm toàn bộ 5 năm là 20,0%. Độc tính của phác đồ thường gặp ở độ 1,2. Tác dụng không mong muốn (TDKMM) hay gặp nhất là rụng tóc (37,5%), chán ăn (25,0%)
ít gặp hơn là nôn/buồn nôn (6,7%), tiêu chảy (5,8%), dị ứng (1,6%). Kết luận: Điều trị ung thư vú tái phát di căn bằng phác đồ Paclitaxel có tỷ lệ đáp ứng tương đối tốt, giúp cải thiện thời gian sống không bệnh tiến triển và thời gian sống thêm toàn bộ cho bệnh nhân., Tóm tắt tiếng anh, Describe some clinical and subclinical characteristics of metastatic breast cancer patiens and evaluate the results of paclitaxel regimen for recurrent or metastatic in breast cancer. Patients and methods: A retrospective study on 120 patients with recurrent or metastatic in breast cancer were treated with paclitaxel chemotherapy regimen at Hanoi Oncology Hospital from 01/2018 to 01/2022. Results: 120 patients enrolled, the average age was 59.6 ± 8.8. The overall response rate (ORR) of the regimen was 37.5 %. The mean progression-free survival was 8.6±2.34 months. The rate overall survival 3 years was 35.5%. The rate overall survival 5 years was 20,0%. The common toxicity was hair loss (37,5%), anorexia (25.0%), nausea (6.7%), diarrhea (5.8%)
allergy (1.6%). Conclusion: Treatment of metastatic recurrent breast cancer with Paclitaxel regimen has a relatively good response rate, which improves progression-free survival and overall survival for patients.

Tạo bộ sưu tập với mã QR